<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01639521</url>
  </required_header>
  <id_info>
    <org_study_id>4B-10-5</org_study_id>
    <secondary_id>NCI-2012-00961</secondary_id>
    <nct_id>NCT01639521</nct_id>
  </id_info>
  <brief_title>Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer</brief_title>
  <official_title>Randomized Phase II Trial Of Adjuvant Chemotherapy For Urothelial Carcinoma Comparing GC To Dose-Dense MVAC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is about two chemotherapy study drug combinations (regimens) that are used for
      urothelial (bladder or upper urinary tract) cancer. Both study drug regimens, gemcitabine
      (gemcitabine hydrochloride) plus cisplatin, and high-dose-intensity MVAC (methotrexate,
      vinblastine, doxorubicin plus cisplatin), are standard chemotherapy regimens. Both regimens
      are used to treat people with urothelial cancer that has spread to other organs. Both study
      drug regimens have been proven to be effective in lowering the risk of the cancer coming
      back, but it is not known which regimen is the best. This study hopes to learn whether there
      is a difference in the effectiveness and side effects of these two study drug regimens when
      they are given to people who have had their urothelial cancer completely removed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES

      To estimate the difference in the rate of unacceptable toxicity for dose-dense methotrexate,
      vinblastine, doxorubicin, and cisplatin (MVAC) and gemcitabine and cisplatin (GC) in the
      adjuvant treatment of urothelial cancer.

      SECONDARY OBJECTIVES

      To compare rates of disease recurrence at 3 years between dose-dense MVAC and GC.

      To determine whether molecular markers excision repair cross-complementing-1 (ERCC-1)
      ribonucleoside-diphosphate reductase M-1 (RRM-1), breast cancer 1 (BRCA1) topoisomerase
      2-alpha (Top2A) and protein 53 (p53) can predict those patients more likely to benefit from
      chemotherapy.

      To investigate the potential utility of cytidine deaminase (CDA), ERCC-1, xeroderma
      pigmentosum group D (XPD), glutathione S-transferase P-1 (GSTP-1) and glutathione
      S-transferase M-1 (GSTM-1) as molecular markers which predict occurrence of significant
      toxicity during adjuvant chemotherapy for urothelial cancer.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM A: Patients receive cisplatin intravenously (IV) on day 1 and gemcitabine hydrochloride
      IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence
      of disease progression or unacceptable toxicity.

      ARM B: Patients receive methotrexate IV on day 1, vinblastine IV, doxorubicin hydrochloride
      IV, cisplatin IV on day 2 and pegfilgrastim subcutaneously (SC) on day 3. Treatment repeats
      every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
      After completion of study treatment, patients are followed up every 3 months for 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of funding
  </why_stopped>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of unacceptable toxicity graded according to Common Terminology Criteria (CTC) v4.0</measure>
    <time_frame>Assessed up to 3 years</time_frame>
    <description>80% confidence intervals (CI) will be constructed; for unacceptable toxicity, the confidence interval will be one-sided.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>From radical cystectomy to the time cancer recurrence is detected by clinical findings or during surveillance imaging, at 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Anterior Urethral Cancer</condition>
  <condition>Localized Transitional Cell Cancer of the Renal Pelvis and Ureter</condition>
  <condition>Posterior Urethral Cancer</condition>
  <condition>Recurrent Bladder Cancer</condition>
  <condition>Recurrent Urethral Cancer</condition>
  <condition>Regional Transitional Cell Cancer of the Renal Pelvis and Ureter</condition>
  <condition>Stage III Bladder Cancer</condition>
  <condition>Transitional Cell Carcinoma of the Bladder</condition>
  <condition>Ureter Cancer</condition>
  <condition>Urethral Cancer Associated With Invasive Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A (gemcitabine hydrochloride, cisplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cisplatin IV on day 1 and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (MVAC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive methotrexate IV on day 1 and vinblastine IV, doxorubicin hydrochloride IV, and cisplatin IV on day 2. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (gemcitabine hydrochloride, cisplatin)</arm_group_label>
    <arm_group_label>Arm B (MVAC)</arm_group_label>
    <other_name>CACP</other_name>
    <other_name>CDDP</other_name>
    <other_name>CPDD</other_name>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (gemcitabine hydrochloride, cisplatin)</arm_group_label>
    <other_name>dFdC</other_name>
    <other_name>difluorodeoxycytidine hydrochloride</other_name>
    <other_name>gemcitabine</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm B (MVAC)</arm_group_label>
    <other_name>amethopterin</other_name>
    <other_name>Folex</other_name>
    <other_name>methylaminopterin</other_name>
    <other_name>Mexate</other_name>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinblastine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm B (MVAC)</arm_group_label>
    <other_name>Velban</other_name>
    <other_name>Velsar</other_name>
    <other_name>VLB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm B (MVAC)</arm_group_label>
    <other_name>ADM</other_name>
    <other_name>ADR</other_name>
    <other_name>Adria</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm B (MVAC)</arm_group_label>
    <other_name>Filgrastim SD-01</other_name>
    <other_name>GCSF-SD01</other_name>
    <other_name>Neulasta</other_name>
    <other_name>SD-01 sustained duration G-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm A (gemcitabine hydrochloride, cisplatin)</arm_group_label>
    <arm_group_label>Arm B (MVAC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed high-grade urothelial carcinoma, stage T3bN0, T4N0 or any T
             stage with lymph node involvement, completely resected; including upper tract
             urothelial carcinoma

          -  The dominant histology must be transitional cell or urothelial but foci of other
             histologies less than 20 percent of the total tumor volume are permitted

          -  Absence of metastatic disease on radiographic imaging

          -  Patients must be enrolled and able to start treatment within 90 days of radical
             cystectomy or radical nephrectomy

          -  Creatinine less than institutional upper limit of normal (ULN) or clearance greater or
             equal to 50 mL/min (may be calculated by Cockcroft-Gault formula or measured from
             24-hour urine collection)

          -  Serum total bilirubin less or equal to 1.5 x ULN (except for patients with Gilbert's)

          -  Alkaline phosphatase less or equal to 2.5 x ULN

          -  Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvate
             transaminase (SGPT) less or equal to 2.5 x ULN

          -  White blood cells (WBC) greater or equal to 3000

          -  Absolute neutrophil count (ANC) greater or equal to 1500

          -  Hemoglobin (Hb) greater or equal to 9

          -  Platelets greater or equal to 100,000

          -  Normal left ventricular ejection fraction, by echocardiogram or multi gated
             acquisition scan (MUGA)

          -  Patients must be recovered from surgery

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Willing and able to provide informed consent

          -  Willingness to use barrier contraception during study period

        Exclusion Criteria:

          -  The presence of significant pleural effusion or ascites

          -  Prior systemic chemotherapy for urothelial carcinoma including neoadjuvant
             chemotherapy (prior intravesical therapy is permitted)

          -  History of malignancy within preceding 5 years, aside from non-melanoma skin cancer or
             previously treated or incidentally detected prostate cancer with undetectable PSA
             (after radical cystectomy or prostate cancer therapy)

          -  Peripheral neuropathy greater than grade 1

          -  The presence of active heart disease such as congestive heart failure or unstable
             angina
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanya Dorff</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2012</study_first_submitted>
  <study_first_submitted_qc>July 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2012</study_first_posted>
  <last_update_submitted>January 27, 2014</last_update_submitted>
  <last_update_submitted_qc>January 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Urethral Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Ureteral Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

